Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Hypertensive retinopathy

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    5 result(s) found for: Hypertensive retinopathy. Displaying page 1 of 1.
    EudraCT Number: 2022-002329-84 Sponsor Protocol Number: APHP211039 Start Date*: 2023-01-06
    Sponsor Name:ASSISTANCE PUBLIQUE HOPITAUX DE PARIS (AP-HP)
    Full Title: Eculizumab in hypertensive emergency-associated hemolytic uremic syndrome: a randomized multicenter controlled trial.
    Medical condition: Adult patients with aHUS associated with HE and severe kidney involvement (needing dialysis or serum creatinine ≥ 354µM).
    Disease: Version SOC Term Classification Code Term Level
    20.1 10005329 - Blood and lymphatic system disorders 10079840 Atypical haemolytic uraemic syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-000581-23 Sponsor Protocol Number: CSPP100A2244 Start Date*: 2008-07-28
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, double-masked, placebo-controlled add on study to assess the efficacy of oral aliskiren 300 mg once daily for diabetic macular edema
    Medical condition: Diabetic Macular Edema (DME) in hypertensive patients
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004853 10057915 Diabetic macular oedema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2012-004112-63 Sponsor Protocol Number: DutchSTRIDER Start Date*: 2014-08-13
    Sponsor Name:Academic Medical Center
    Full Title: The Dutch STRIDER (Sildenafil TheRapy In Dismal prognosis Early-onset intrauterine growth Restriction) Trial
    Medical condition: Fetal growth restriction
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-003144-23 Sponsor Protocol Number: PANDA Start Date*: 2014-02-03
    Sponsor Name:King's College London [...]
    1. King's College London
    2. Guy's and St Thomas' NHS Foundation Trust
    Full Title: Pregnancy And chronic hypertension: NifeDipine or labetalol as Antihypertensive treatment
    Medical condition: Chronic hypertension in pregnancy
    Disease: Version SOC Term Classification Code Term Level
    16.1 10047065 - Vascular disorders 10036695 Primary hypertension LLT
    16.1 10047065 - Vascular disorders 10039834 Secondary hypertension PT
    16.1 10047065 - Vascular disorders 10015488 Essential hypertension PT
    Population Age: Adults Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-003200-39 Sponsor Protocol Number: 13/0077 Start Date*: 2014-04-01
    Sponsor Name:University College London
    Full Title: A phase II, single centre, randomised, placebo-controlled, 3-part trial to assess the safety, tolerability and efficacy of Zibotentan in patients with renal disease secondary to scleroderma
    Medical condition: Renal complications of systemic sclerosis (scleroderma renal crisis and chronic kidney disease).
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004857 10064848 Chronic kidney disease LLT
    16.1 10028395 - Musculoskeletal and connective tissue disorders 10061087 Connective tissue disorder PT
    16.1 10028395 - Musculoskeletal and connective tissue disorders 10018124 Generalized scleroderma LLT
    16.1 100000004857 10069339 Acute kidney injury LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 10 20:02:02 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA